APO Research
Talk to an analyst

APO RESEARCH · REPORT

Spinal and Bulbar Muscular Atrophy Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Spinal and Bulbar Muscular Atrophy Treatment Market Outlook and Growth Opportunities 2026

19 December 2025194 pages

Choose your research edition.

Industry ResearchSpinal and Bulbar Muscular Atrophy Treatment Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Spinal and Bulbar Muscular Atrophy Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Spinal and Bulbar Muscular Atrophy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spinal and Bulbar Muscular Atrophy Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Spinal and Bulbar Muscular Atrophy Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Spinal and Bulbar Muscular Atrophy Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Spinal and Bulbar Muscular Atrophy Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Spinal and Bulbar Muscular Atrophy Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Spinal and Bulbar Muscular Atrophy Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Spinal and Bulbar Muscular Atrophy Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Spinal and Bulbar Muscular Atrophy Treatment market include Sanofi, Johnson & Johnson, Pfizer, GlaxoSmithKline, AbbVie, Century Pharmaceuticals, Boehringer Ingelheim International and Astellas Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Spinal and Bulbar Muscular Atrophy Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Spinal and Bulbar Muscular Atrophy Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Spinal and Bulbar Muscular Atrophy Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Spinal and Bulbar Muscular Atrophy Treatment market.

Spinal and Bulbar Muscular Atrophy Treatment Segment by Company

Sanofi

Johnson & Johnson

Pfizer

GlaxoSmithKline

AbbVie

Century Pharmaceuticals

Boehringer Ingelheim International

Astellas Pharma

Spinal and Bulbar Muscular Atrophy Treatment Segment by Type

5α-Reductase Inhibitors

Gonadotropin-releasing Hormone Agonists

Spinal and Bulbar Muscular Atrophy Treatment Segment by Application

Hospitals

Ambulatory Surgical Centers

Orthopedic Clinics

Spinal and Bulbar Muscular Atrophy Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Spinal and Bulbar Muscular Atrophy Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Spinal and Bulbar Muscular Atrophy Treatment key companies, revenue, market share, and recent developments.

3. To split the Spinal and Bulbar Muscular Atrophy Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Spinal and Bulbar Muscular Atrophy Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Spinal and Bulbar Muscular Atrophy Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Spinal and Bulbar Muscular Atrophy Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal and Bulbar Muscular Atrophy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spinal and Bulbar Muscular Atrophy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal and Bulbar Muscular Atrophy Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Spinal and Bulbar Muscular Atrophy Treatment industry.

Chapter 3: Detailed analysis of Spinal and Bulbar Muscular Atrophy Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Spinal and Bulbar Muscular Atrophy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Spinal and Bulbar Muscular Atrophy Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Spinal and Bulbar Muscular Atrophy Treatment Industry Trends Table 2. Spinal and Bulbar Muscular Atrophy Treatment Industry Drivers Table 3. Spinal and Bulbar Muscular Atrophy Treatment Industry Opportunities and Challenges Table 4. Spinal and Bulbar Muscular Atrophy Treatment Industry Restraints Table 5. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Company (2021-2026) Table 7. Global Spinal and Bulbar Muscular Atrophy Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Spinal and Bulbar Muscular Atrophy Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Spinal and Bulbar Muscular Atrophy Treatment Company, Product Type & Application Table 10. Global Spinal and Bulbar Muscular Atrophy Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Spinal and Bulbar Muscular Atrophy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 5α-Reductase Inhibitors Table 15. Significant Companies of Gonadotropin-releasing Hormone Agonists Table 16. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type (2021-2026) Table 20. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of Ambulatory Surgical Centers Table 23. Significant Companies of Orthopedic Clinics Table 24. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application (2021-2026) Table 28. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application (2027-2032) Table 29. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Region (2021-2026) Table 32. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Region (2027-2032) Table 34. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Market Share by Country (2027-2032) Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 43. Sanofi Recent Development Table 44. Johnson & Johnson Company Information Table 45. Johnson & Johnson Business Overview Table 46. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 48. Johnson & Johnson Recent Development Table 49. Pfizer Company Information Table 50. Pfizer Business Overview Table 51. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 53. Pfizer Recent Development Table 54. GlaxoSmithKline Company Information Table 55. GlaxoSmithKline Business Overview Table 56. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 58. GlaxoSmithKline Recent Development Table 59. AbbVie Company Information Table 60. AbbVie Business Overview Table 61. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 63. AbbVie Recent Development Table 64. Century Pharmaceuticals Company Information Table 65. Century Pharmaceuticals Business Overview Table 66. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 68. Century Pharmaceuticals Recent Development Table 69. Boehringer Ingelheim International Company Information Table 70. Boehringer Ingelheim International Business Overview Table 71. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 73. Boehringer Ingelheim International Recent Development Table 74. Astellas Pharma Company Information Table 75. Astellas Pharma Business Overview Table 76. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 78. Astellas Pharma Recent Development Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Spinal and Bulbar Muscular Atrophy Treatment Product Image Figure 2. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Spinal and Bulbar Muscular Atrophy Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 5α-Reductase Inhibitors Image Figure 8. Gonadotropin-releasing Hormone Agonists Image Figure 9. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. Ambulatory Surgical Centers Image Figure 14. Orthopedic Clinics Image Figure 15. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • 5α-Reductase Inhibitors
  • Gonadotropin-releasing Hormone Agonists
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • GlaxoSmithKline
  • AbbVie
  • Century Pharmaceuticals
  • Boehringer Ingelheim International
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Spinal and Bulbar Muscular Atrophy Treatment Market Dynamics
  1. 2.1 Spinal and Bulbar Muscular Atrophy Treatment Industry Trends
  2. 2.2 Spinal and Bulbar Muscular Atrophy Treatment Industry Drivers
  3. 2.3 Spinal and Bulbar Muscular Atrophy Treatment Industry Opportunities and Challenges
  4. 2.4 Spinal and Bulbar Muscular Atrophy Treatment Industry Restraints
3 Spinal and Bulbar Muscular Atrophy Treatment Market by Company
  1. 3.1 Global Spinal and Bulbar Muscular Atrophy Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Spinal and Bulbar Muscular Atrophy Treatment Company Ranking (2024-2026)
  4. 3.4 Global Spinal and Bulbar Muscular Atrophy Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Spinal and Bulbar Muscular Atrophy Treatment Company Product Type and Application
  6. 3.6 Global Spinal and Bulbar Muscular Atrophy Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Spinal and Bulbar Muscular Atrophy Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Spinal and Bulbar Muscular Atrophy Treatment Market by Type
  1. 4.1 Spinal and Bulbar Muscular Atrophy Treatment Type Introduction
  2. 4.1.1 5α-Reductase Inhibitors
  3. 4.1.2 Gonadotropin-releasing Hormone Agonists
  4. 4.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Type
  5. 4.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type (2021-2032)
5 Spinal and Bulbar Muscular Atrophy Treatment Market by Application
  1. 5.1 Spinal and Bulbar Muscular Atrophy Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.1.3 Orthopedic Clinics
  5. 5.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Application
  6. 5.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application (2021-2032)
6 Spinal and Bulbar Muscular Atrophy Treatment Regional Value Analysis
  1. 6.1 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Country, 2025 VS 2032
7 Spinal and Bulbar Muscular Atrophy Treatment Country-level Value Analysis
  1. 7.1 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Spinal and Bulbar Muscular Atrophy Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Spinal and Bulbar Muscular Atrophy Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 Century Pharmaceuticals
  32. 8.6.1 Century Pharmaceuticals Company Information
  33. 8.6.2 Century Pharmaceuticals Business Overview
  34. 8.6.3 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  36. 8.6.5 Century Pharmaceuticals Recent Developments
  37. 8.7 Boehringer Ingelheim International
  38. 8.7.1 Boehringer Ingelheim International Company Information
  39. 8.7.2 Boehringer Ingelheim International Business Overview
  40. 8.7.3 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  42. 8.7.5 Boehringer Ingelheim International Recent Developments
  43. 8.8 Astellas Pharma
  44. 8.8.1 Astellas Pharma Company Information
  45. 8.8.2 Astellas Pharma Business Overview
  46. 8.8.3 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  48. 8.8.5 Astellas Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst